4. Loser: Bristol-Myers Squibb

Company: Bristol-Myers Squibb
Symbol: $BMY
Beginning Price: $35.01
Ending Price: $32.62
Loss: 6.83%

The most dramatic move on Bristol-Myers Squibb's ($BMY) 2012 stock-performance chart was the one-day drop on Aug. 2, when the company suspended Phase II testing of a very expensive hepatitis C drug. After buying drug developer Inhibitex in January for $2.5 billion, primarily for its lead hep C candidate, Bristol-Myers carried the research forward--until a patient developed heart failure. Within two weeks, the company had stopped the trial, stopped the program and taken a $1.8 billion charge for tossing that once-promising drug into the dustbin.

That failure, along with some other recent setbacks, has put CEO Lamberto Andreotti into the doghouse. But as November wound down, the company won European approval, along with Pfizer ($PFE), for its much-anticipated blood thinner Eliquis. And in collaboration with AstraZeneca ($AZN), it launched a new diabetes drug in the U.K. and EU. If Bristol-Myers can persuade the FDA to go along on both drugs, too, then Andreotti may find his way back into the sunshine again.

For more:
Special Report: Top buyers by activity, Q1-Q3 2012
Pfizer, Bristol-Myers win landmark European approval for Eliquis
Does Bristol's tarnished rep put CEO among the year's worst?
BMS results crater on 96% drop in Plavix sales
Setbacks tarnish Bristol-Myers' 'string of pearls'


4. Loser: Bristol-Myers Squibb

Suggested Articles

Viatris, the merger of Mylan and Pfizer's Upjohn, has fleshed out its board and C-suite with a raft of Pfizer and Mylan veterans.

An FDA approval of Lilly’s Cyramza combo would pit it against AZ's Tagrisso, which has charted impressive survival gains in EGFR-positive lung cancer.

Fujifilm Diosynth Biotechnologies last year committed 10 billion yen toward its manufacturing operations. It has now kicked off one of those projects.